The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL)

Journal of Leukocyte Biology

Volumn 84, Issue 3, 2008, Pages 651-

  Corallini, Federica ^a   Celeghini, Claudio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Apoptosis; Cell cycle progression; CpG oligodeoxynucleotides; MDM2 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; NUTLIN; OLIGODEOXYNUCLEOTIDE; PROTEIN P53; UNCLASSIFIED DRUG;

B CELL LEUKEMIA; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CLINICAL PRACTICE; CYTOSTASIS; EXPERIMENTAL MOUSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IN VITRO STUDY; LETTER; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 50849103036     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0408222     Document Type: Letter

References (10)

1. Secchiero, P., Melloni, E., Tiribelli, M., Gonelli, A., Zauli, G. (2008) Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. J. Leukoc. Biol. 83, 434-437.
2. Saddler, C., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., Erba, H., Shedden, K., Wang, S., Malek, S. N. (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111, 1584-1593.
3. Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., Zauli, G. (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107, 4122-4129.
4. Coll-Mulet, L., Iglesias-Serret, D., Santidrián, A. F., Cosialls, A. M., de Frias, M., Castaño, E., Campàs, C., Barragán, M., de Sevilla, A. F., Domingo, A., Vassilev, L. T., Pons, G., Gil, J. (2006) MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107, 4109-4114.
5. Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., Andreeff, M. (2006) Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108, 993-1000.
6. Jahrsdörfer, B., Wooldridge, J. E., Blackwell, S. E., Taylor, C. M., Link, B. K., Weiner, G. J. (2005) Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia 19, 759-766.
7. Messmer, B. T., Messmer, D., Allen, S. L., Kolitz, J. E., Kudalkar, P., Cesar, D., Murphy, E. J., Koduru, P., Ferrarini, M., Zupo, S., Cutrona, G., Damle, R. N., Wasil, T., Rai, K. R., Hellerstein, M. K., Chiorazzi, N. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115, 755-764.
8. Longo, P. G., Laurenti, L., Gobessi, S., Petlickovski, A., Pelosi, M., Chiusolo, P., Sica, S., Leone, G., Efremov, D. G. (2007) The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21, 110-120.
9. Richardson, S. J., Matthews, C., Catherwood, M. A., Alexander, H. D., Carey, B. S., Farrugia, J., Gardiner, A., Mould, S., Oscier, D., Copplestone, J. A., Prentice, A. G. (2006) ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107, 3584-3592.
10. Byrd, J. C., Rai, K., Peterson, B. L., Appelbaum, F. R., Morrison, V. A., Kolitz, J. E., Shepherd, L., Hines, J. D., Schiffer, C. A., Larson, R. A. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53.